Compare WLYB & PAHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLYB | PAHC |
|---|---|---|
| Founded | 1807 | 1946 |
| Country | United States | United States |
| Employees | 5200 | N/A |
| Industry | Books | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | N/A | 2014 |
| Metric | WLYB | PAHC |
|---|---|---|
| Price | $36.71 | $52.63 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $34.33 |
| AVG Volume (30 Days) | 230.0 | ★ 222.4K |
| Earning Date | 03-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.89% | 0.92% |
| EPS Growth | N/A | ★ 1883.33 |
| EPS | N/A | ★ 1.32 |
| Revenue | N/A | ★ $833,350,000.00 |
| Revenue This Year | $0.02 | $17.03 |
| Revenue Next Year | $2.32 | $3.82 |
| P/E Ratio | ★ $15.27 | $39.62 |
| Revenue Growth | N/A | ★ 4.12 |
| 52 Week Low | $29.16 | $16.16 |
| 52 Week High | $45.16 | $56.30 |
| Indicator | WLYB | PAHC |
|---|---|---|
| Relative Strength Index (RSI) | 65.39 | 59.22 |
| Support Level | $36.20 | $37.09 |
| Resistance Level | $38.63 | $56.14 |
| Average True Range (ATR) | 0.33 | 2.28 |
| MACD | 0.60 | -0.16 |
| Stochastic Oscillator | 94.35 | 73.36 |
John Wiley & Sons Inc is a publisher and a trusted leader in research and learning. The company segment includes: Research, which includes the reporting lines of Research Publishing and Research Solutions, and Learning includes the Academic and Professional reporting lines and consists of publishing, courseware, and assessments. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.